J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

Johnson & Johnson has announced the submission of an extension of indication application to the European Medicines Agency (EMA) seeking approval of Akeega (niraparib/abiraterone acetate) with ...

In patients on a daily prednisolone dose of less than 0.4 mg/kg/day or 20 mg, a 1–3-mg/day decrease weekly is selected. The final target dosage of systemic prednisolone is ≤0.2 mg/kg/day or 10 ...

Conversely, an initial prednisolone dose of 10 mg/day was felt adequate by Behn et al., [8] with only 8/67 (11.9%) PMR patients needing an increase in dosage.

Objective: To examine whether acute glucocorticoid (GC) intake alters performance and selected hormonal and metabolic variables during submaximal exercise. Methods: In total, 14 recreational male ...

Amneal plans to launch the product in the third quarter of 2025. According to IQVIA, U.S. annual sales for prednisolone acetate ophthalmic suspension for the 12 months ended April 2025 were about ...

Key complex product approval in the Affordable Medicines segment this yearCommercial launch planned for third quarter of 2025 ...

Prednisolone acetate ophthalmic suspension, USP 1% is a sterile, topical anti-inflammatory agent for ophthalmic use and is indicated for treating steroid-responsive ocular inflammation.

Key complex product approval in the Affordable Medicines segment this year Commercial launch planned for third quarter of 2025 BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal ...

Key Takeaways FDA approved prednisolone acetate ophthalmic suspension for steroid-responsive ocular inflammation, referencing Pred Forte by Allergan, Inc. Amneal's approval highlights their R&D ...

Prednisolone and antihistamine tablets provided similar levels of relief for patients with allergic rhinitis during tree pollen season, according to a study published in Clinical and Translational ...